Nectar Lifescience Ltd

{"maxBuyBackPrice":27,"totalAggregatedAmount":81,"offerType":"Tender Offer"}

{"description":"Nectar Lifescience posted a consolidated net loss of Rs 67.92 crore for the March 2026 quarter; full-year loss widened to Rs 292.89 crore from Rs 113.68 crore a year earlier, with no sales reported.","url":"https://www.business-standard.com/markets/capital-market-news/nectar-lifescience-reports-consolidated-net-loss-of-rs-67-92-crore-in-the-march-2026-quarter-126060100766_1.html","sentiment":"Negative","domain":"Business Standard"}

{"description":"Nectar Lifesciences shares surged 18% on December 4, 2025, following a ₹81-crore buyback announcement at a 51% premium. The buyback will repurchase 3 crore shares at ₹27 each, with a record date set for December 24, 2025. Despite a significant net loss reported, the stock has gained 45.5% in the past month.","url":"https://www.cnbctv18.com/market/nectar-lifesciences-share-price-buyback-announcement-51-percent-premium-volumes-record-date-19780313.htm","sentiment":"Positive","domain":"CNBCTV18"}

{"description":"Nectar Lifesciences shares fell 20% following the announcement of selling its core business for ₹1,270 crore, part of a strategy to streamline operations and enhance focus.","url":"https://www.cnbctv18.com/market/nectar-lifesciences-share-price-sale-api-formulation-menthol-biz-ceph-1290-crore-debt-value-19633319.htm","sentiment":"Negative","domain":"CNBCTV18"}

{"description":"Nectar Lifesciences sells its core API and formulation business for Rs 1290 crore, leading to a 20% stock crash. This business accounted for 98.33% of the company's total revenue.","url":"https://www.financialexpress.com/business/industry-nectar-lifesciences-sells-core-api-and-formulation-business-for-rs-1290-crore-stock-crashes-20-3906784/","sentiment":"Negative","domain":"The Financial Express"}

{"description":"Nectar Lifesciences shares fell to a 52-week low of ₹18.6, down 19.6% in trade, prompting investor concerns.","url":"https://www.business-standard.com/markets/news/nectar-lifesciences-shares-hit-52-week-low-sale-of-core-business-ceph-lifesciences-125070800244_1.html","sentiment":"Negative","domain":"Business Standard"}

{"description":"Nectar Lifesciences shares dropped nearly 20% to ₹18.60 after announcing the sale of its API and formulations business to Ceph Lifesciences for ₹1,270 crore, hitting a 52-week low.","url":"https://www.msn.com/en-in/money/markets/nectar-lifesciences-soars-around-20-hits-52-week-low-after-announcing-1270-crore-biz-sale-to-ceph-lifesciences/ar-AA1I9Y8x?ocid=BingNewsVerp","sentiment":"Positive","domain":"Mint on MSN"}